On the other hand, ibrutinib can also indirectly affect T cell exhaustion by reducing PD-L1 expression in CLL (14) or other immune cells, such as myeloid cells that also express BTK (15, 16), and thus indirectly mitigate T cell exhaustion. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.